EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Respiratory Syncytial Virus Exceeded SARS‐CoV‐2 and Influenza in Lower Respiratory Infection and Mortality Rates Among Patients With Hematologic Malignancies During the 2023–2024 Respiratory Virus Season

Tali Shafat, Amy Spallone, Fareed Khawaja, Ying Jiang, Jennifer Jackson, Lior Nesher, Roy F Chemaly

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Tali Shafat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hematologic Neoplasms, COVID-19, Respiratory Syncytial Virus Infections, Influenza, Human. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory viral infections (RVIs) significantly impact patients with hematologic malignancies (HMs). During the 2023–2024 respiratory viral (RV) season, we observed a decline in SARS‐CoV‐2‐related hospitalizations in our center compared to the two previous seasons. Given the changing epidemiology of RVIs in the post‐pandemic era, the low acceptance of SARS‐CoV‐2 and influenza vaccination, and the availability of new respiratory syncytial virus (RSV) vaccines in 2023, we aimed to compare outcomes of RSV, influenza, and SARS‐CoV‐2 infections in patients with HMs during the 2023–2024 RV season.

Methods

We retrospectively analyzed adults with HMs diagnosed with RSV, influenza, or SARS‐CoV‐2 between October 2023 and April 2024. The primary outcomes were lower respiratory tract infection (LRI), hospitalization, and 30‐day all‐cause mortality.

Results

We identified 503 patients with 536 consecutive RVIs: 50.0% with SARS‐CoV‐2, 26.1% with RSV, and 22.2% with influenza (1.7% co‐infections). Among RSV‐infected patients, 50.7% developed LRI, compared to 41.2% with influenza and 39.2% with SARS‐CoV‐2 ( p = 0.076). The 30‐day all‐cause mortality was 9.3% for RSV, 7.6% for influenza, and 3.4% for SARS‐CoV‐2 ( p = 0.037). In the multivariable analysis, RSV was associated with higher LRI rate compared to SARS‐CoV‐2, along with older age, refractory/relapsed cancer, nosocomial infections, and lymphopenia. Older age, allogeneic hematopoietic cell transplantation, nosocomial infections, and LRIs were associated with increased mortality.

Conclusions

During the 2023–2024 RV season, the clinical impact of these viruses on patients with HMs remains significant, with higher morbidity and mortality from RSV, highlighting the persistent unmet need for better management strategies for RVIs in the post‐pandemic era. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsCOVID-19Respiratory Syncytial Virus InfectionsInfluenza, HumanRespiratory Tract InfectionsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedHospitalizationSARS-CoV-2AdultSeasonsRespiratory Syncytial Virus, HumanCoinfection

Stichwörter der Autor:innen

SARS‐CoV‐2hematologic malignancyinfluenzarespiratory syncytial virusrespiratory viral infection

Autor:innen und Institutionen

  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Basel, Switzerland.
  • Department of Infection Control, Chief Quality Office, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Infectious Disease Institute, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Zitieren

APA

Shafat, T., Spallone, A., Khawaja, F., Jiang, Y., Jackson, J., Nesher, L., & Chemaly, R. F. (2025). Respiratory Syncytial Virus Exceeded SARS‐CoV‐2 and Influenza in Lower Respiratory Infection and Mortality Rates Among Patients With Hematologic Malignancies During the 2023–2024 Respiratory Virus Season. Transplant Infectious Disease. https://doi.org/10.1111/tid.70113

Vancouver

Shafat T, Spallone A, Khawaja F, Jiang Y, Jackson J, Nesher L, et al. Respiratory Syncytial Virus Exceeded SARS‐CoV‐2 and Influenza in Lower Respiratory Infection and Mortality Rates Among Patients With Hematologic Malignancies During the 2023–2024 Respiratory Virus Season. Transplant Infectious Disease. 2025. doi:10.1111/tid.70113

BibTeX
@article{Shafat2025,
  author = {Shafat, Tali and Spallone, Amy and Khawaja, Fareed and Jiang, Ying and Jackson, Jennifer and Nesher, Lior and Chemaly, Roy F},
  title = {Respiratory Syncytial Virus Exceeded SARS‐CoV‐2 and Influenza in Lower Respiratory Infection and Mortality Rates Among Patients With Hematologic Malignancies During the 2023–2024 Respiratory Virus Season},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70113}
}
Kostenlos starten →